New Haven drug developer Achillion Pharmaceuticals Inc. widened its fourth-quarter and full-year losses in 2011 as it works to commercialize a pipeline of treatments for hepatitis C and other blood-borne infectious diseases.
For three months ended Dec. 31, Achillion lost $12.4 million, or 18 cents a diluted share, up from $6.2 million, or 11 cents a share, lost the same period in 2010.
Fourth-quarter revenues from contract lab work fell to $62,000 from $2 million a year earlier.
For 2011, Achillion lost $44.2 million, or 69 cents a diluted share, wider than the $25.5 million, or 57 cents a share, lost a in 2010.
Achillion ended 2011 with cash and marketable securities to fund operations totaling $79.9 million, up from $55.2 million in 2010.
